Amgen Inc. $AMGN Shares Sold by Avity Investment Management Inc.

Key Points

• Avity Investment Management cut its Amgen stake by 30.9%, selling 32,766 shares and leaving it with 73,373 shares valued at about $20.71 million per the latest SEC filing.
• Amgen beat quarterly expectations (EPS $5.29 vs. $4.76; revenue $9.87B vs. $9.46B), raised FY guidance (FY2026 EPS 21.600–23.000), and saw analysts lift price targets even as the consensus rating remains "Hold" with an average target of $354.00.
• The company announced a quarterly dividend of $2.52 (annualized $10.08, ~2.8% yield; ex-dividend May 15) and about 76.5% of its stock is held by hedge funds and other institutional investors.

Avity Investment Management Inc. lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 30.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,373 shares of the medical research company's stock after selling 32,766 shares during the period. Avity Investment Management Inc.'s holdings in Amgen were worth $20,706,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its holdings in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. boosted its position in Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Alberta Investment Management Corp acquired a new stake in Amgen in the second quarter valued at $474,000. Finally, LSV Asset Management increased its position in shares of Amgen by 176.7% in the second quarter. LSV Asset Management now owns 301,100 shares of the medical research company's stock valued at $84,070,000 after buying an additional 192,300 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on AMGN shares. Mizuho lifted their price target on Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Weiss Ratings restated a "buy (b)" rating on shares of Amgen in a research report on Monday, December 29th. Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an "outperform" rating in a report on Thursday, January 29th. Finally, Erste Group Bank upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $354.00.

Amgen Price Performance

Amgen stock opened at $361.13 on Wednesday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The firm has a 50 day moving average price of $359.26 and a 200 day moving average price of $326.77. The company has a market cap of $194.67 billion, a price-to-earnings ratio of 25.38, a PEG ratio of 3.63 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen's revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's dividend payout ratio (DPR) is 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported stronger-than-expected results and raised FY guidance, supporting fundamentals and cash flow — a key reason some investors remain constructive. MarketBeat Earnings & Guidance
• Positive Sentiment: Analysts lifted Amgen’s fair-value estimate on growing confidence in execution and the MariTide obesity program, which boosts upside expectations if clinical/exclusivity risks are managed. Yahoo: Narrative Shifting
• Positive Sentiment: Large investor interest: Ken Fisher’s firm increased its Amgen stake, a vote of confidence from a prominent institutional investor. Yahoo: Ken Fisher Doubles Position
• Neutral Sentiment: Amgen is being watched by retail and professional traders (trending coverage), which can amplify moves but doesn’t by itself change fundamentals. Zacks: Trending Stock
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent/zeroed out and is not signaling a clear squeeze or covering dynamic at this time.
• Neutral Sentiment: Amgen’s shares were reported to outperform many peers on a relative-basis despite the intraday decline, indicating sector/stock-specific flows rather than a company-specific collapse. MarketWatch: Outperforms Peers
• Negative Sentiment: Amgen (with peers) is reportedly joining a drug-discount initiative (TrumpRx), which could pressure pricing and margins for certain products if discounts are material. Benzinga: TrumpRx Participation
• Negative Sentiment: Analyst upgrades and MariTide optimism are tempered by exclusivity and long-term earnings debate — unresolved regulatory/IP questions could cap upside until clearer trial and exclusivity outcomes arrive. Yahoo: Exclusivity Concerns

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.